SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares

Key Points

• Insider sale: Philippe Menu sold 5,000 SOPHiA GENETICS shares at an average price of $7.52, generating $37,600. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, leaving him with 218,387 shares.
• Recent performance: SOPH shares traded at $7.50, near their 52-week high of $7.88 and well above the 52-week low of $3.10. The company recently reported quarterly revenue of $23.31 million but missed EPS expectations, posting a loss of $0.26 per share.
• Analyst outlook: Ratings are mixed, with three Buy, one Hold and one Sell recommendation; the consensus rating is Hold with a $10 average price target. HC Wainwright and BTIG both raised their price targets following the earnings report.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 5,000 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $7.52, for a total transaction of $37,600.00. Following the completion of the transaction, the insider directly owned 218,387 shares of the company's stock, valued at $1,642,270.24. This represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.66, for a total value of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Price Performance

Shares of SOPH traded down $0.12 during midday trading on Friday, hitting $7.50. 193,279 shares of the company traded hands, compared to its average volume of 223,733. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 52 week low of $3.10 and a 52 week high of $7.88. The firm has a 50 day moving average of $5.84 and a 200-day moving average of $5.21. The stock has a market cap of $629.17 million, a price-to-earnings ratio of -6.52 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. On average, analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Silverberg Bernstein Capital Management LLC lifted its stake in SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock worth $257,000 after purchasing an additional 4,155 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock valued at $148,000 after buying an additional 6,205 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock worth $6,976,000 after buying an additional 9,800 shares during the period. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the first quarter worth approximately $50,000. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on SOPH. HC Wainwright boosted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source